Drug-induced QT interval prolongation: Do we know the risks?;Prolongación del intervalo QT inducido por fármacos: ¿conocemos sus riesgos?

Medicina Clinica

Volumn 144, Issue 6, 2015, Pages 269-274

  Villamañán, Elena ^a   Armada, Eduardo ^a   Ruano, Margarita ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Drug interactions; Drugs; QT interval prolongation; Risk factors; Torsade de pointes

Indexed keywords

CARDIOVASCULAR AGENT;

ADVERSE DRUG REACTION; HUMAN; QT INTERVAL; QT PROLONGATION; REVIEW; RISK FACTOR; SUDDEN CARDIAC DEATH; CHEMICALLY INDUCED; COMPLICATION; DEATH, SUDDEN, CARDIAC; DRUG INTERACTION; LONG QT SYNDROME;

DEATH, SUDDEN, CARDIAC; DRUG INTERACTIONS; HUMANS; LONG QT SYNDROME; RISK FACTORS;

EID: 84924094359     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2014.01.027     Document Type: Review

References (39)

1. C. Asmundis, and P. Brugada Epidemiología de la muerte súbita cardiaca Rev Esp Cardiol 13 2013 2 6
2. J. Marrugat, R. Elosua, and M. Gil Muerte súbita (I). Epidemiología de la muerte súbita cardiaca en España Rev Esp Cardiol 52 1999 717 725
3. C.M. Pratt, P.S. Greenway, M.H. Schoenfeld, M.L. Hibben, and J.A. Reiffel Exploration of the precision of classifying sudden cardiac death: Implications for the interpretation of clinical trials Circulation 93 1996 519 524
4. M. Josephson, and H.J. Wellens Implantable defibrillators and sudden cardiac death Circulation 109 2004 2685 2691
5. D.P. Zipes, and H.J. Wellens Sudden cardiac death Circulation 98 1998 2334 2351
6. C. Van Noord, M. Eijgelsheim, and B.H. Stricker Drug- and non-drug-associated QT interval prolongation Br J Clin Pharmacol 70 2010 16 23
7. F. De Ponti, E. Poluzzi, A. Cavalli, M. Recanatini, and N. Montanaro Safety of non-antiarrythmic drugs that prolong the QT interval or induce tosade de pointes: An overview Drug Saf 25 2002 263 286
8. D.M. Roden Drug-induced prolongation of the QT interval N Engl J Med 350 2004 1013 1022
9. R.R. Shah Drug-induced QT interval prolongation: Does ethnicity of the thorough QT study population matter? Br J Clin Pharmacol 75 2013 347 358
10. International Conference on Harmonization. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential of nonantiarrhythmic drugs. EMA/CHMP/ICH/310133/2008. ICH guideline E14, 2012.
11. Food and Drug Administration. International conference harmonization guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. FDA; 2005 [consultado 21 Ene 2014]. Disponible en: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073153.pdf.
12. A. Selzer, and H.W. Wray Quinidine syncope, paroxysmal ventricular fibrillations occurring during treatment of chronic atrial arrythmias Circulation 30 1964 17 26
13. F. Dessertenne La tachycardie ventricularie à deux froyers opposés variables Arch Mal Coeur Vaiss 59 1966 263 272
14. B.J. Drew, M.J. Ackerman, M. Funk, W.B. Gibler, P. Kligfield, and V. Menom Prevention of torsade de pointes in hospitals settings: A scientific statement from the American Heart Association and American College of Cardiology Foundation Circulation 121 2010 1047 1060
15. S.H. Hohnloser, T. Klingenheben, and B.N. Singh Amiodarone-associated proarrhythmic effects. A review with special reference to torsades de pointes tachycardia Ann Intern Med 121 1994 529 535
16. R.L. Woosley, Y. Chen, J.P. Freiman, and R.A. Gillis Mechanism of the cardiotoxic actions of terfenadine JAMA 269 1993 1532 1536
17. Y.G. Yap, and A.J. Camm Drug induced QTprolongation and torsades de pointes Heart 89 2003 1363 1372
18. E.C. Owens Jr., and T.D. Nolin Antimicrobials-associated QT interval prologation: Points of interest Clin Infect Dis 43 2006 1603 1611
19. A. Zambon, H.P. Friz, P. Contiero, and G. Corrao Effect of macrolide and fluoroquinolone antibacterials on the risk of ventricular arrhythmia and cardiac arrest Drug Saf 32 2009 159 167
20. A.W. Vogt, and R.A. Zollo Long Q-T syndrome associated with oral erythromycin used in preoperative bowel preparation Anesth Analg 85 1997 1011 1013
21. S.J. Tschida, D.R. Guay, R.J. Straka, L.L. Hoey, R. Johanning, and K. Vance-Bryan QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: A prospective evaluation and review of the literature Pharmacotherapy 16 1996 663 674
22. M.D. Drici, B.C. Knollmann, W.X. Wang, and R.L. Woosley Cardiac actions of erythromycin: Influence of female sex JAMA 280 1998 1774 1776
23. D. Shaffer, S. Singer, J. Korvick, and P. Honig Concomitant risk factors in reports of torsades de pointes associated with macrolide use: Review of the United States Food and Drug Administration Adverse Event Reporting System Clin Infect Dis 35 2002 197 200
24. W.A. Ray, K.T. Murray, S. Meredith, S.S. Narasimhulu, K. Hall, and C.M. Stein Oral erythromycin use and the risk of sudden cardiac death N Engl J Med 351 2004 1089 1096
25. S.M. Straus, M.C. Sturkenboom, G.S. Bleumink, J.P. Dielemann, J. van der Lei, and P.A. de Graeff Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death Eur Heart J 26 2005 2007 2012
26. E. Poluzzi, R. Raschke, U. Moretti, and F. de Ponti Drug-induced torsades de pointes: Data mining of the public version of the FDA Adverse Event Reporting System (AERS) Pharmacoepidemiol Drug Saf 18 2009 512 518
27. W.A. Ray, K.T. Murray, K. Hall, P.G. Arbogast, and M. Stein Azithromycin and the risk of cardiovascular death N Engl J Med 366 2012 1881 1890
28. B.D. Anson, J.G. Weaver, M.J. Ackerman, O. Akinsete, K. Henry, and C.T. January Blockade of HERG channels by HIV protease inhibitors Lancet 365 2005 682 686
29. K. Hunt, C.A. Hughes, and C. Hills-Nieminen Protease inhibitor-associated QT interval prolongation Ann Pharmacother 45 2011 1544 1550
30. A.F. Tarabar, R.S. Hoffman, and L.S. Nelson Citalopram overdose: Late presentation of torsades de pointes (TdP) with cardiac arrest J Med Toxicol 4 2008 101 105
31. K.J. Chung, Y.C. Wang, B.M. Liu, and R.B. Supernaw Management of ventricular dysrhythmia secondary to trazadone overdose J Emerg Med 35 2008 171 174
32. W.A. Ray, C.P. Chung, K.T. Murray, K. Hall, and C.M. Stein Atypical antipsychotic drugs and the risk of sudden cardiac death N Engl J Med 360 2009 225 235
33. CredibleMeds. Composite list of all QTdrugs and the list of drugs to avoid for patients with congenital LQTS [consultado 25 Oct 2013]. Disponible en: http://www.crediblemeds.org/everyone/composite-list-all-qtdrugs/?rf=All
34. S.M. Al-Khatib, N.M. LaPointe, J.M. Kramer, and R.M. Califf What clinicians should know about the QT interval JAMA 289 2003 2120 2127
35. M.J. Armahizer, A.L. Seybert, P.L. Smithburger, and S.L. Kane-Gill Drug-drug interaccions contributing to QT prolongation in cardiac intensive care units J Crit Care 28 2013 243 249
36. D.P. Zipes, A.J. Camm, M. Borggrefe, A.E. Buxton, B. Chaitman, and M. Fromer ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) J Am Coll Cardiol 48 2006 e247 e346
37. E.C. Li, J.S. Esterly, S. Pohl, S.D. Scott, and B.F. McBride Drug-induced QT-interval prolongation: Considerations for clinicians Pharmacotherapy 30 2010 684 701
38. E. Villamañán, A. Herrero, and R. Álvarez-Sala Prescripción electrónica asistida como nueva tecnología para la seguridad del paciente hospitalizado Med Clin (Barc) 136 2011 398 402
39. Mayo Clinic Creates Institution. Wide electronic prolonged QT interval warning system [consultado 25 Oct 2013]. Disponible en: http://newsnetwork.mayoclinic.org/discussion/first-electronic-prolonged-qt-interval-warning-system.